Impact of MMP2 rs243865 and MMP3 rs3025058 Polymorphisms on Clinical Findings in Alzheimer’s Disease Patients
Table 3
Allele and genotype frequencies of MMP3 polymorphism rs3025058 (-1171 5A/6A) in AD patients and controls.
SNP/model
Allele/genotype
AD subjects ()
Controls ()
Univariate analysis
Multivariate analysis
OR (95% CI)
OR (95% CI)
rs3025058
6A
171 (50.00%)
318 (51.62%)
—
—
5A
171 (50.00%)
298 (48.38%)
0.68
1.07 (0.82-1.39)
—
—
Codominant
6A/6A
41 (23.98%)
76 (24.67%)
1.00
1.00
5A/6A
89 (52.04%)
166 (53.90%)
0.82
0.99 (0.63-1.57)
0.98
1.00 (0.62-1.63)
5A/5A
41 (23.98%)
66 (21.43%)
1.15 (0.67-1.98)
1.06 (0.59-1.88)
Dominant
6A/6A
41 (23.98%)
76 (24.67%)
1.00
1.00
5A/6A+5A/5A
130 (76.02%)
232 (75.33%)
0.86
1.04 (0.67-1.61)
0.94
1.02 (0.64-1.62)
Recessive
6A/6A+5A/6A
130 (76.02%)
242 (78.57%)
1.00
1.00
5A/5A
41 (23.98%)
66 (21.43%)
0.52
1.16 (0.74-1.80)
0.82
1.05 (0.66-1.68)
Overdominant
5A/5A+6A/6A
82 (47.96%)
142 (46.10%)
5A/6A
89 (52.04%)
166 (53.90%)
0.70
0.93 (0.64-1.35)
0.90
0.98 (0.66-1.45)
Abbreviations: CI: confidence interval; : number; OR: odds ratio. Allele and genotype frequencies are given as absolute numbers with percentages in parentheses. Univariate analysis is based on the Pearson chi-squared test. Multivariate analysis is adjusted for sex, age, and APOEε4 positivity. is considered statistically significant.
